دورية أكاديمية
Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
| العنوان: | Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations |
|---|---|
| المؤلفون: | Urska Janzic, Walid Shalata, Katarzyna Szymczak, Rafał Dziadziuszko, Marko Jakopovic, Giannis Mountzios, Adam Płużański, Antonio Araujo, Andriani Charpidou, Abed Agbarya |
| المصدر: | International Journal of Molecular Sciences, Vol 24, Iss 16, p 12840 (2023) |
| بيانات النشر: | MDPI AG, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Biology (General) LCC:Chemistry |
| مصطلحات موضوعية: | non-small-cell lung cancer, BRAF V600E mutation, cMET exon 14 skipping mutation, real-world data, targeted therapy, first-line treatment, Biology (General), QH301-705.5, Chemistry, QD1-999 |
| الوصف: | BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs. 39.1% (p = 0.04), respectively. The type of treatment in first-line TT vs. other affected time to treatment discontinuation (TTD) was 11.6 m vs. 4.6 m (p= 0.006). The overall survival for the whole group was 15.4 m and was not statistically affected by the type of treatment (19.2 m vs. 13.5 m; p = 0.83). |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 24161284 1422-0067 1661-6596 |
| Relation: | https://www.mdpi.com/1422-0067/24/16/12840; https://doaj.org/toc/1661-6596; https://doaj.org/toc/1422-0067 |
| DOI: | 10.3390/ijms241612840 |
| URL الوصول: | https://doaj.org/article/367e3ed462af4cc4823f46838d886b3a |
| رقم الأكسشن: | edsdoj.367e3ed462af4cc4823f46838d886b3a |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 24161284 14220067 16616596 |
|---|---|
| DOI: | 10.3390/ijms241612840 |